Risk Factors for Fluconazole-Resistant Candidemia

被引:86
作者
Garnacho-Montero, Jose [1 ,4 ]
Diaz-Martin, Ana [1 ,4 ]
Garcia-Cabrera, Emilio [2 ,4 ]
Perez de Pipaon, Maite Ruiz [3 ,4 ]
Hernandez-Caballero, Clara [1 ]
Aznar-Martin, Javier [3 ,4 ]
Cisneros, Jose M. [3 ,4 ]
Ortiz-Leyba, Carlos [1 ,4 ]
机构
[1] Virgen del Rocio Univ Hosp, Intens Care Unit, Crit Care & Emergency Dept, Seville 41013, Spain
[2] Spanish Network Res Infect Dis REIPI, Seville, Spain
[3] Virgen del Rocio Univ Hosp, Infect Dis Microbiol & Prevent Med Clin Unit, Seville 41013, Spain
[4] Univ Seville, Hosp Univ Virgen del Rocio, Seville Biomed Res Inst, CSIC, Seville, Spain
关键词
BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; NON-ALBICANS CANDIDEMIA; ANTIFUNGAL PROPHYLAXIS; KRUSEI FUNGEMIA; GLABRATA; SUSCEPTIBILITY; METAANALYSIS; SURVEILLANCE; MORTALITY;
D O I
10.1128/AAC.00479-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Previous studies have sought to determine the risk factors associated with candidemia caused by non-albicans Candida spp. or with potentially fluconazole-resistant Candida spp. (C. glabrata and C. krusei). Non-albicans Candida strains are a heterogeneous group that includes species with different levels of virulence, and only a limited number of C. glabrata isolates are resistant to fluconazole. We set out to identify the risk factors associated with microbiologically proven fluconazole-resistant candidemia. A prospective study including adult patients with candidemia was performed. Data were collected on patient demographics; underlying diseases; exposure to corticosteroids, antibiotics, or fluconazole; and invasive procedures. Risk factors associated either with non-albicans Candida spp. or potentially fluconazole-resistant Candida spp. (C. glabrata or C. krusei) or with Candida spp. with microbiologically confirmed fluconazole resistance were assessed using logistic regressions. We included 226 candidemia episodes. Non-albicans Candida isolates accounted for 53.1% of the fungal isolates, but only 18.2% of the cases were caused by potentially fluconazole-resistant organisms. Thirty isolates exhibited microbiologically confirmed fluconazole resistance. The multivariate analysis revealed that independent predictors associated with fluconazole-resistant Candida spp. were neutropenia (odds ratio [OR] = 4.94; 95% confidence interval [CI] = 1.50 to 16.20; P = 0.008), chronic renal disease (OR = 4.82; 95% CI = 1.47 to 15.88; P = 0.01), and previous fluconazole exposure (OR = 5.09; 95% CI = 1.66 to 15.6; P = 0.004). Independently significant variables associated with non-albicans Candida bloodstream infection or with potentially fluconazole-resistant Candida spp. did not include previous fluconazole exposure. We concluded that prior fluconazole treatment is an independent risk factor only for candidemia caused by microbiologically confirmed fluconazole resistant species. Our findings may be of value for selecting empirical antifungal therapy.
引用
收藏
页码:3149 / 3154
页数:6
相关论文
共 31 条
  • [1] Epidemiology and predictors of mortality in cases of Candida bloodstream infection:: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003
    Almirante, B
    Rodríguez, D
    Park, BJ
    Cuenca-Estrella, M
    Planes, AM
    Almela, M
    Mensa, J
    Sanchez, F
    Ayats, J
    Gimenez, M
    Saballs, P
    Fridkin, SK
    Morgan, J
    Rodriguez-Tudela, JL
    Warnock, DW
    Pahissa, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (04) : 1829 - 1835
  • [2] Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility
    Arendrup, M. C.
    Fuursted, K.
    Gahrn-Hansen, B.
    Schonheyder, H. C.
    Knudsen, J. D.
    Jensen, I. M.
    Bruun, B.
    Christensen, J. J.
    Johansen, H. K.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (05) : 487 - 494
  • [3] Epidemiological trends in nosocomial candidemia in intensive care
    Bassetti, M
    Righi, E
    Costa, A
    Fasce, R
    Molinari, MP
    Rosso, R
    Pallavicini, FB
    Viscoli, C
    [J]. BMC INFECTIOUS DISEASES, 2006, 6 (1)
  • [4] Antifungal prophylaxis for severely neutropenic chemotherapy recipients -: A meta-analysis of randomized-controlled clinical trials
    Bow, EJ
    Laverdiére, M
    Lussier, N
    Rotstein, C
    Cheang, MS
    Ioannou, S
    [J]. CANCER, 2002, 94 (12) : 3230 - 3246
  • [5] Choi Hee Kyoung, 2009, Korean Journal of Internal Medicine, V24, P263, DOI 10.3904/kjim.2009.24.3.263
  • [6] Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia
    Clancy, CJ
    Yu, VL
    Morris, AJ
    Snydman, DR
    Nguyen, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3171 - 3177
  • [7] Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis
    Cruciani, Mario
    Mengoli, Carlo
    Malena, Marina
    Bosco, Oliviero
    Serpelloni, Giovanni
    Grossi, Paolo
    [J]. LIVER TRANSPLANTATION, 2006, 12 (05) : 850 - 858
  • [8] Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds
    Cuenca-Estrella, Manuel
    Gomez-Lopez, Alicia
    Mellado, Emilia
    Monzon, Araceli
    Buitrago, Maria J.
    Rodriguez-Tudela, Juan L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (05) : 2192 - 2195
  • [9] Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients
    Davis, Susan L.
    Vazquez, Jose A.
    McKinnon, Peggy S.
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (04) : 568 - 573
  • [10] Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections:: Differences in risk factors and outcome
    Dimopoulos, George
    Ntziora, Fotinie
    Rachiotis, George
    Armaganidis, Apostolos
    Falagas, Matthew E.
    [J]. ANESTHESIA AND ANALGESIA, 2008, 106 (02) : 523 - 529